pharmaphorum

JANUARY 5, 2021

Roche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough status from the FDA. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.

Chemotherapy 52

Chemotherapy Immunity Immunization Labelling 52

Pharmaceutical Technology

MAY 2, 2023

IO agents include the classes of immune checkpoint modulators, cell therapies, bispecific antibodies, oncolytic viruses, therapeutic vaccines, and cytokines. IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000.

Immunity 52

Immunity Immunization Vaccines 52

pharmaphorum

APRIL 5, 2022

The one-year survival rate with the drug was 73%, compared to 58% in a group receiving standard-of-care – off-label immune checkpoint inhibitors used for other forms of melanoma like Merck & Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Yervoy (ipilimumab) or chemotherapy with dacarbazine.

Labelling 52

Labelling Chemotherapy Immunity Immunization 52

European Pharmaceutical Review

DECEMBER 27, 2023

This is especially important due to the two unique toxicities of CAR T cells, namely CRS and the neurology toxicities that subsequently received the term immune effector cell- associated neurotoxicity syndrome (ICANS). This is in addition to its considerable price tag. References Liu D. Journal of Hematology & Oncology. 2019;12(1).

Adverse Reactions 83

Adverse Reactions Immunity Immunization Medical Schools 83